NCT02752776

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

An Open-label, Prospective, Non-randomized, Multicenter Study to Evaluate Clear Skin Effect on Health Related Quality of Life Outcomes at 16 and 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis Treated With Secukinumab 300 mg s.c. With or Without Previous Exposure to Systemic Therapy.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,660 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Secukinumab	Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).

Timeline

• Start date: 2016-03-17
• Primary completion: 2018-03-28
• Completion: 2018-03-28
• First posted: 2016-04-27
• Last updated: 2019-09-25
• Results posted: 2019-09-25

Locations

215 sites across 17 countries: Belgium, Bulgaria, Czechia, Estonia, France, Germany, Greece, Israel, Italy, Latvia, Lithuania, Poland, Portugal, Romania, Slovakia, Spain, United Kingdom